Lipton, Richard B.
Lombard, Louise
Ruff, Dustin D.
Krege, John H.
Loo, Li Shen
Buchanan, Andrew
Melby, Thomas E.
Buse, Dawn C.
Funding for this research was provided by:
Eli Lilly and Company (N/A)
Article History
Received: 3 December 2019
Accepted: 7 February 2020
First Online: 24 February 2020
Ethics approval and consent to participate
: All participants provided written informed consent. The study was conducted in compliance with the International Council for Harmonisation principles of Good Clinical Practice. Ethics review boards approved the study protocol and the informed consent form prior to study commencement.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: Richard B Lipton has received consultant fees, honoraria, and/or research grants from Alder, Allergan, Inc., Amgen, Biohaven, Dr. Reddy’s Laboratories, eNeura, electroCore, Eli Lilly and Company, Novartis, Teva, and Trigemina. He has stock options in eNeura and Biohaven. Dawn C Buse has received grant support and honoraria from Allergan, Amgen/Novartis, Biohaven, Dr. Reddy’s Laboratories/Promeius, Eli Lilly and Company, and Teva. Louise Lombard, Dustin D Ruff, John H Krege, Li Shen Loo, and Andrew Buchanan were employees and minor stockholders of Eli Lilly and Company. Thomas E Melby was an employee of Syneos Health, Inc., under contract to Eli Lilly and Company.